Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer - PubMed (original) (raw)

Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer

Tarek A Bismar et al. Histopathology. 2012 Mar.

Abstract

Aims: Recently, ETS-related gene (ERG) gene rearrangements, phosphatase tensin homologue (PTEN) deletions and serine protease inhibitor Kazal type 1 (SPINK1) overexpression were investigated as potential markers for molecularly subtyping prostate cancer (PCA). However, their incidence and co-association in castration-resistant PCA (CRPC) has not been characterized fully.

Methods and results: A cohort of 59 CRPC patients was investigated for ERG rearrangements, PTEN deletions and androgen receptor (AR) amplification by fluorescence in-situ hybridization. SPINK1 overexpression was assessed by immunohistochemistry. ERG rearrangements and PTEN deletions were detected in 22 of 53 (41.5%) and 35 of 55 (63.6%) of cases, with 15 of 22 (68.1%) of ERG rearrangements occurring through deletions. SPINK1 overexpression occurred in three of 51 (5.8%) of cases exclusively in non-ERG rearranged and AR amplification was detected in 12 of 49 (24.4%) of cases. Only PTEN deletions showed intrafocal heterogeneity occurring in nine of 35 (25.7%) of cases. PTEN deletions were significantly associated with each of ERG rearrangements occurring by deletions only (P = 0.001), AR amplification (P = 0.002) and SPINK1 overexpression (P = 0.002). None of the SPINK1 overexpressing tumours showed AR amplification (P = 0.005) and all occurred in PTEN deleted foci (P = 0.002).

Conclusion: Te study supports the heterogeneous nature of CRPC and confirms a significant association between PTEN, ERG, AR and SPINK1. Characterizing combined markers will aid in defining PCA subgroups relevant to prognosis contributing to the design of improved therapeutic approaches for CRPC.

PubMed Disclaimer

Cited by

Molecular pathways and targets in prostate cancer.
Shtivelman E, Beer TM, Evans CP. Shtivelman E, et al. Oncotarget. 2014 Sep 15;5(17):7217-59. doi: 10.18632/oncotarget.2406. Oncotarget. 2014. PMID: 25277175 Free PMC article. Review.
The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.
Fiandalo MV, Wu W, Mohler JL. Fiandalo MV, et al. Curr Drug Targets. 2013 Apr;14(4):420-40. doi: 10.2174/1389450111314040004. Curr Drug Targets. 2013. PMID: 23565755 Free PMC article. Review.
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.
Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, Perner S, Bismar TA, Erbersdobler A, Dhir R, Nelson JB, Nanus DM, Rubin MA. Mosquera JM, et al. Neoplasia. 2013 Jan;15(1):1-10. doi: 10.1593/neo.121550. Neoplasia. 2013. PMID: 23358695 Free PMC article.
Clinical implications of PTEN loss in prostate cancer.
Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, Lotan TL. Jamaspishvili T, et al. Nat Rev Urol. 2018 Apr;15(4):222-234. doi: 10.1038/nrurol.2018.9. Epub 2018 Feb 20. Nat Rev Urol. 2018. PMID: 29460925 Free PMC article. Review.
The Association between Cyclin Dependent Kinase 2 Associated Protein 1 (CDK2AP1) and Molecular Subtypes of Lethal Prostate Cancer.
Gamallat Y, Bakker A, Khosh Kish E, Choudhry M, Walker S, Aldakheel S, Seyedi S, Huang KC, Ghosh S, Gotto G, Bismar TA. Gamallat Y, et al. Int J Mol Sci. 2022 Nov 1;23(21):13326. doi: 10.3390/ijms232113326. Int J Mol Sci. 2022. PMID: 36362115 Free PMC article.

Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer - PubMed (original) (raw)